Table 1.
Oligonucleotide | Formulation | Company or sponsor | Indication | Stage of development | Status |
---|---|---|---|---|---|
STAT3 DECOY | DNA competitive inhibitor | University of Pittsburgh | Head and neck cancer | Phase 0 | Completed |
AZD9150 | Antisense Oligonucleotide inhibitor | AstraZeneca, Ionis Pharmaceuticals | Diffuse large B-cell lymphoma, advanced lymphoma | Phase I/II | Active, not recruiting |
AZD9150 | Antisense Oligonucleotide inhibitor | National Cancer Institute (NCI) | Ovarian cancer/neoplasms, gastrointestinal cancer/neoplasms | Phase II | Terminated |
AZD9150 | Antisense Oligonucleotide inhibitor | AstraZeneca, Ionis Pharmaceuticals | Advanced adult hepatocellular carcinoma, metastatic hepatocellular carcinoma | Phase I | Completed |
AZD9150 in combination with MEDI4736 |
Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody |
MedImmune | Diffuse large B-cell lymphoma | Phase I | Recruiting |
AZD9150 in combination with MEDI4736 |
Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody |
AstraZeneca, MedImmune | Metastatic head and neck squamous cell carcinoma | Phase I/II | Recruiting |
AZD9150 in combination with MEDI4736 |
Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody |
M. D. Anderson Cancer Center, AstraZeneca | Advanced pancreatic, non-small cell lung and colorectal cancers | Phase II | Not yet recruiting |
Information collected from http://www.clinicaltrials.gov